Literature DB >> 7029410

The clinical use of cocaine.

J M Verlander, M E Johns.   

Abstract

Cocaine is an extremely useful drug for various otolaryngologic procedures, and as an anesthetic it is unrivaled for vasoconstriction and decongestion. Its use should not be restricted any more than any other controlled drug. In the majority of procedures 200 to 300 mg. of cocaine is sufficient to obtain adequate anesthesia, decongestion, and vasoconstriction. In cases in which this amount may be less than adequate, injections of lidocaine with epinephrine can be used to supplement the anesthetic action of cocaine. It is difficult to imagine a case requiring 1000 mg. of cocaine as some physicians have reported in the past. To prevent mistaken injections of cocaine solutions, we recommend that they be colored by the pharmacy. To prevent overdosing we recommend starting with a known amount and not exceeding this total dose. We have chosen 200 to 300 mg. as our total dose for most adult procedures. Some pharmacies prepare 250 mg. of cocaine base in saline for those who prefer a cocaine "slush"; this, too, would be acceptable.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7029410

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  4 in total

1.  Topical anaesthesia for repair of minor lacerations.

Authors:  D H Bass; P J Wormald; J McNally; H Rode
Journal:  Arch Dis Child       Date:  1990-11       Impact factor: 3.791

2.  Epistaxis and nasotracheal intubation--prevention with vasoconstrictor spray.

Authors:  J O'Hanlon; K W Harper
Journal:  Ir J Med Sci       Date:  1994-02       Impact factor: 1.568

3.  The effects of medial prefrontal cortex infusions of cocaine in a runway model of drug self-administration: evidence of reinforcing but not anxiogenic actions.

Authors:  Daniel Guzman; Justin M Moscarello; Aaron Ettenberg
Journal:  Eur J Pharmacol       Date:  2009-01-10       Impact factor: 4.432

Review 4.  Clinical use of cocaine. A review of the risks and benefits.

Authors:  R M Middleton; M B Kirkpatrick
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.